0000950170-25-106633 Sample Contracts
ContractLicense Agreement • August 11th, 2025 • Agenus Inc • Biological products, (no disgnostic substances) • London
Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential.
AGENUS INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 11th, 2025 • Agenus Inc • Biological products, (no disgnostic substances) • Delaware
This Securities Purchase Agreement (this “Agreement”) is made and entered into as of June 3, 2025, by and among Agenus Inc., a Delaware corporation (the “Company”), and Zynext Ventures USA LLC (“Purchaser”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 11th, 2025 • Agenus Inc • Biological products, (no disgnostic substances) • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”) is dated June 3, 2025 (the “Effective Date”), by and between Agenus West LLC, a limited liability company organized under the laws of the State of Delaware (“Agenus West”) and Agenus Inc., a Delaware corporation (“Agenus Parent” and together with Agenus West, each a “Seller” and collectively, “Sellers”), on the one hand, and Zydus Pharmaceuticals (USA) Inc., a corporation organized under the laws of the State of New Jersey (“Buyer”), on the other hand. Sellers and Buyer are sometimes referred to herein as the “Parties” and each as a “Party.”